Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma
Authors:
- Stephan SpahnSSStephan Spahn
- Daniel RoesslerDRDaniel Roessler
- Radu PompiliaRPRadu Pompilia
- Gisela GabernetGGGisela Gabernet
- Beryl Primrose GladstoneBGBeryl Primrose Gladstone
- Marius HorgerMHMarius Horger
- Saskia BiskupSaskia Biskup
- Magdalena FeldhahnMFMagdalena Feldhahn
- Sven NahnsenSNSven Nahnsen
- Franz J. HilkeFHFranz J. Hilke
- Bernhard ScheinerBSBernhard Scheiner
- Jean-François DufourJDJean-François Dufour
Open Access
Abstract
Immune checkpoint inhibitors (ICIs) belong to the therapeutic armamentarium in advanced hepatocellular carcinoma (HCC). However, only a minority of patients benefit from immunotherapy. Therefore, we aimed to identify indicators of therapy response. This multicenter analysis included 99 HCC patients. Progression-free (PFS) and overall survival (OS) were studied by Kaplan-Meier analyses for clinical parameters using weighted log-rank testing. Next-generation sequencing (NGS) was performed in a subset of 15 patients. The objective response (OR) rate was 19% median OS (mOS)16.7 months. Forty-one percent reached a PFS > 6 months; these patients had a significantly longer mOS (32.0 vs. 8.5 months). Child-Pugh (CP) A and B patients showed a mOS of 22.1 and 12.1 months, respectively. Ten of thirty CP-B patients reached PFS > 6 months, including 3 patients with an OR. Tumor mutational burden (TMB) could not predict responders. Of note, antibiotic treatment within 30 days around ICI initiation was associated with significantly shorter mOS (8.5 vs. 17.4 months). Taken together, this study shows favorable outcomes for OS with low AFP, OR, and PFS > 6 months. No specific genetic pattern, including TMB, could identify responders. Antibiotics around treatment initiation were associated with worse outcome, suggesting an influence of the host microbiome on therapy success.Keywords
This publication has 49 references indexed in Scilit:
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.Journal of Clinical Oncology, 2019
- Hepatocellular CarcinomaNew England Journal of Medicine, 2019
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2019
- Targeted and Immune-Based Therapies for Hepatocellular CarcinomaGastroenterology, 2019
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular CarcinomaNew England Journal of Medicine, 2018
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Hepatocellular carcinomaThe Lancet, 2018
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008